OVID
OVID
NASDAQ · Biotechnology

Ovid Therapeutics Inc

$1.60
+0.15 (+10.34%)
As of Feb 8, 2:05 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 29.94M 31.11M 33.06M
Net Income -8,740,072 -8,350,078 -10,285,734
EPS
Profit Margin -29.2% -26.8% -31.1%
Rev Growth -9.8% +19.5% +23.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 30.67M 32.20M 24.28M
Total Equity 123.93M 114.62M 121.51M
D/E Ratio 0.25 0.28 0.20
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -14,130,650 -13,566,183 -16,328,398
Free Cash Flow -7,098,906 -8,976,737 -6,780,942